A Central Role for RAF→MEK→ERK Signaling in the Genesis of Pancreatic Ductal Adenocarcinoma.

KRAS mutation is a hallmark of pancreatic ductal adenocarcinoma (PDA), but remains an intractable pharmacological target. Consequently, defining RAS effector pathway(s) required for PDA initiation and maintenance is critical to improve treatment of this disease. Here we demonstrate that expression o...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Collisson, Eric A., Trejo, Christy, Silva, Jillian, Gu, Shenda, Korkola, James E., Heiser, Laura, Charles, Roch-Philippe, Rabinovich, Brian A., Hann, Byron, Dankort, David, Spellman, Paul T., Phillips, Wayne, Gray, Joe W., McMahon, Martin
Format: Artigo
Idioma:Inglês
Publicat: 2012
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3425446/
https://ncbi.nlm.nih.gov/pubmed/22628411
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-11-0347
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars